[Ocular disorders of anticancer drugs--ocular side effects].
Although there are some sporadic reports about the ocular side effects (see below-named ocular disorders) of anticancer drugs, extremely few well-organized reports have been published. We report have eye disorders caused by anticancer drugs on the ocular surface (eyelids, conjunctiva, cornea), retina, optic nerve, and sites of the lacrymal ducts. For disorders of the anterior ocular segment, we use gefitinib (Iressa®) and erlotinib (Tarceba®), cetuximab (Arbitax®) for trichomegaly while for lacrymal duct disorders and retinas with corneal problems revolt biochemistry, S-1 (TS-1®), erlotinib, docetaxel, paclitaxel and tamoxifen, paclitaxel, tamoxifen, optic neuropathy with 5-fluorouracil (5-FU), S-1 and docetaxel have been reported. Eye disorders can be relieved by discontinuation of the anticancer drug, but one may cause irreversible change, and early diagnosis and treatment are required. In future, there is a need for examinations for large-scale eye disorders due to anticancer drugs and their prevention (about S-1 in particular) including the provision of information to ophthalmologists.
Kashiwagi
Hiroya
H
Division of Opthalmology, Shizuoka Cancer Center, Sunto-gun, Shizuoka, Japan.
D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D005128:Eye Diseases / Q000139:chemically induced* / Q000175:diagnosis / Q000628:therapy; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy
D000970:Antineoplastic Agents